Methotrexate-Induced Pulmonary Fibrosis: Diagnosis and Management
Immediate Action Required
Stop methotrexate immediately upon suspicion of pulmonary toxicity and initiate corticosteroid therapy. 1
Clinical Presentation
Methotrexate-induced pneumonitis typically presents with an acute to subacute course characterized by:
Critical distinction: While MTX-pneumonitis usually has an acute/subacute presentation, progressive pulmonary fibrosis can develop with chronic exposure, though this is less common. 2, 4
Diagnostic Approach
Imaging Findings
Chest X-ray and CT are essential when pulmonary symptoms develop in any patient on methotrexate. 3
High-resolution CT typically reveals:
- Diffuse bilateral ground-glass opacities (most common pattern) 5
- Patchy bilateral ground-glass opacity with or without reticulation 5
- Interlobular septal thickening 6
- Pleural thickening 6
- Consolidation (less common) 5
- Centrilobular ill-defined nodules (rare) 5
Radiologic patterns: Non-specific interstitial pneumonia (NSIP) is more common than bronchiolitis obliterans organizing pneumonia (BOOP). 2
Histopathological Features
If biopsy is performed, expect:
- Interstitial infiltrates by lymphocytes, histiocytes, and eosinophils 2
- Non-caseating granulomas (may or may not be present) 2
Essential Rule-Out
Infection, particularly Pneumocystis carinii pneumonia, must be excluded before attributing symptoms to methotrexate toxicity. 1, 3 This is critical as immunosuppression from methotrexate increases infection risk.
Management Protocol
Step 1: Discontinue Methotrexate
Immediately stop methotrexate when pulmonary toxicity is suspected. 1, 6, 3
Step 2: Initiate Corticosteroids
- High-dose systemic corticosteroids are the treatment of choice 6, 3
- Example regimen: 32 mg/day methylprednisolone or equivalent 6
- Patients with severe pulmonary compromise require hospitalization, supplemental oxygen, and high-dose corticosteroids 3
Step 3: Supportive Care
Step 4: Follow-up Imaging
- Most patients show rapid improvement within days to weeks of treatment 5
- Repeat CT at approximately 1 month to document radiologic improvement 6, 5
- Average improvement time: 31 days (range 3-76 days) 5
Prognostic Considerations
Important caveat: Patients with pre-existing interstitial lung disease or pulmonary fibrosis at presentation have worse prognosis and may show refractory disease despite treatment. 5 These patients may not fully recover even after methotrexate discontinuation and corticosteroid therapy.
Prevention and Monitoring
Baseline Assessment
- Chest X-ray before initiating methotrexate 1
- Pulmonary function tests may be useful for baseline measurements 1
Patient Education
All patients prescribed methotrexate must be counseled about:
- Early signs of pulmonary toxicity 1, 3
- Need to report respiratory symptoms immediately 6, 3
- This is potentially life-threatening but treatable if caught early 3
Risk Factors
While several risk factors have been suggested (genetic, environmental, pre-existing lung disease), none have been consistently validated to predict who will develop toxicity. 1, 2, 3 Pre-existing lung disease increases risk of methotrexate pneumonitis, but the overall risk remains uncertain. 7
Special Consideration: Methotrexate Use in Existing Lung Disease
For patients with mild, stable, pre-existing lung disease: The 2021 ACR guideline conditionally recommends methotrexate over alternative DMARDs for treating inflammatory arthritis in patients with moderate-to-high disease activity, despite the increased risk. 7 However, if ILD develops or worsens while on methotrexate, discontinue the drug immediately. 8, 7